SCHEMBL13304793

SCHEMBL13304793

Bc1cnn2c(NCc3cnc(N)nc3)cc(C3CCCN(C(=O)OCc4ccccc4)C3)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.41
▸ JAK2 O60674 2/20 0.41
▸ JAK1 P23458 2/20 0.41
▸ TYK2 P29597 2/20 0.41
▸ JAK3 P52333 2/20 0.41
▸ USP30 Q70CQ3 1/20 0.41
▸ GSK3B P49841 4/20 0.41
▸ MAP3K12 Q12852 1/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ CCNA2 P20248 1/20 0.40
▸ CDK2 P24941 1/20 0.40
▸ CCNA1 P78396 1/20 0.40
▸ LCK P06239 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ CCNT1 O60563 1/20 0.37
▸ CDK9 P50750 1/20 0.37
▸ GRIN2B Q13224 3/20 0.37
▸ ENPP2 Q13822 2/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CYP2C9 P11712 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13305685 0.91 MAP3K12 (0.43) MAPK1JAK2JAK1TYK2JAK3
SCHEMBL12953762 0.91 GSK3B (0.51) MAPK1JAK2JAK1TYK2JAK3
SCHEMBL13305009 0.85 USP30 (0.45) MAPK1JAK2JAK1TYK2JAK3
SCHEMBL12953558 0.83 GSK3B (0.50) MAPK1JAK2JAK1TYK2JAK3
SCHEMBL13305198 0.80 GSK3B (0.56) GSK3BCHEK1CDK2GRIN2BCYP2D6
SCHEMBL14043203 0.80 TRPC3 (0.44) USP30GSK3BCHEK1CCNA2CDK2
SCHEMBL12953266 0.80 GSK3B (0.51) JAK2JAK1TYK2JAK3USP30
SCHEMBL12954179 0.80 GSK3B (0.67) GSK3BCDK2
SCHEMBL13304833 0.79 CA2 (0.52) USP30GSK3BGRIN2BENPP2CYP2D6
SCHEMBL13304821 0.79 GSK3B (0.53) GSK3BCHEK1CCNA2CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537116-B1 PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES SCHERING CORP (US) 2010-06-02 — — EP disclosed
Send feedback